18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study

European Journal of Nuclear Medicine

Volumn 28, Issue 6, 2001, Pages 711-720

  Tiling, Reinhold ^a   Linke, Rainer ^a   Untch, Michael ^b   Richter, Almuth ^b   Fieber, Siegrid ^a   Brinkbäumer, Kirsten ^a   Tatsch, Klaus ^a   Hahn, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

18F FDG PET; Breast carcinoma; Neoadjuvant chemotherapy; Single photon emission tomography; Technetium 99m sestamibi scintimammography

Indexed keywords

EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; PATIENT MONITORING; PEROPERATIVE CARE; POSITRON EMISSION TOMOGRAPHY; SCINTIMAMMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR REGRESSION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MAMMOGRAPHY; MIDDLE AGED; SCINTISCANNING; STANDARD;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RADIOPHARMACEUTICALS; REFERENCE STANDARDS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034744104     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100539     Document Type: Article

References (37)

1. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62:2507-2516.
2. Mansi JL, Smith IE, Walsh G, et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 1989; 25:1623-1627.
3. Bonadonna G, Veronesi U, Brambilla CM, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of 3 centimeters or more. J Natl Cancer Inst 1990; 82:1539-1545.
4. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
5. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-2493.
6. Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 1994; 18:63-69.
7. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46:2578-2581.
8. Buzdar A, Montague E, Barker J, Hortobagyi G, Blumenschein G. Management of inflammatory carcinoma of the breast with combined modality approach - an update. Cancer 1981; 47:2537-2542.
9. Hortobagyi G, Blumenschein G, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983; 51:763-768.
10. Maini CL, Tofani A, Sciuto R, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med 1997; 38:1546-1551.
11. Moscovic EC, Mansi JL, King DM, Murch CR, Smith IE. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 1993; 47:339-344.
12. Segel MC, Paulus DD, Hortobagyi GN, et al. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 1988; 169:49-54.
13. Khalkhali I, Cutrone J, Mena I, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196:421-426.
14. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36:1784-1789.
15. Palmedo H, Schomburg A, Grünwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37:626-630.
16. Tiling R, Khalkhali I, Sommer H, et al. Role of technetium- 99m sestamibi scintimammography and contrast enhanced magnetic resonance imaging for the evaluation of indeterminate mammograms. Eur J Nucl Med 1997; 24:1221-1229.
17. Tiling R, Sommer H, Pechmann M, et al. Comparison of Tc-99m sestamibi scintimammography with contrast enhanced MRI for the diagnosis of breast lesions. J Nucl Med 1997; 38:58-62.
18. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicenter trial. Eur J Nucl Med 1998; 25:375-385.
19. Avril N, Dose J, Jaenicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14:1848-1857.
20. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2- deoxy-D-glucose. Radiology 1991; 179:765-770.
21. Adler LP, Crowe JP, Al-Kaisi MK, et al. Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
22. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
23. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37:931-938.
24. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999; 85:2410-2423.
25. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-369.
26. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990; 66:1387-1391.
27. Machiavelli M, Romero A, Peres J, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4:125-131.
28. Vinnicombe SJ, Mac Vicar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 1996; 198:333-340.
29. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33:862-866.
30. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radial 1997; 70:452-458.
31. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmakokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. MRI Clin North Am 1994; 2:633-658.
32. Gilles R, Guinebretiere J, Toussaint C, et al. Locally advanced breast cancer: contrast enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: 633-638.
33. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996; 78:91-100.
34. Carvalho PA, Chiu ML, Kronauge FK, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33:1516-1521.
35. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1829-1838.
36. Delmon-Moinegon LI, Piwnica-Worms D, Abbeele ADVD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50:2198-2202.
37. McEwan AJB. Positron-emission tomography and predicting tumor treatment response. In: Chapman JD, Peters LJ, Withers RH, eds. Prediction of tumor treatment response. Elmsford, N.Y.: Pergamon Press; 1989; 20:277-295.